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Abstract
The objective of the research was to estimate early and long-term results of secondary cytoreductive surgery performed for
recurrent ovarian cancer with involvement of urinary organs.
Materials and methods. The study included 62 patients with recurrent ovarian cancer treated in the Institute of General
and Emergency Surgery named after V.T. Zaitsev of the Academy of Medical Sciences of Ukraine during January 2009
– September 2015. Selection criteria for secondary cytoreductive surgery were the following: recurrent ovarian cancer
with involvement of the bladder and/or the ureter, no urologic surgery during primary cytoreductive surgery, the ECOG
performance status of 0-2. Urological surgery that had been a subject to the analysis was the following: cystoscopy with
or without intraoperative urethral stenting, bladder resection, ureterectomy, ureteral reimplantation, cystectomy with further
reconstruction. Evaluation criteria included the presence and the level of surgical and postoperative urological complications
within 30 days after surgery, relaparatomy rates, postoperative mortality, type of cytoreduction. Long-term results were
evaluated through recurrence rates after secondary cytoreductive surgery, median survival, disease-free survival and overall
survival.
Results. Volumes of performed surgery (excluding urological one) were the following: lymphadenectomy (n=29; 46.7%),
bowel resection (n=17; 27.4%), vascular resection (n=4; 6.5%) and others. Minimally invasive urological surgery included
urethral stenting (n=6; 9.7%) and cystoscopy (n=13; 20.9%). Bladder resection was performed in 26 (41.9%) cases,
cystectomy – in 17 (27.4%) cases. R0 resections were performed in all the cases. Postoperative non-urological complications
were observed in 7 (11.2%) patients. Urological complications were found in 9 (14.5%) patients. Postoperative mortality
was 3.2%. Recurrence was documented in 7 (11.3%) cases. Median survival was 24 months. Follow-up mortality was 30%
(n=18).
Conclusions. The results of combined secondary cytoreductive surgery performed for recurrent ovarian cancer with
involvement of urinary organs indicate the possibility of en bloc resection of tumor and surrounding organs at acceptable
rates of postoperative complications and mortality. Extended combined surgery and even pelvic exenteration are effective in
treatment of patients with recurrent ovarian cancer.
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Problem statement and analysis of the
recent research
Treatment of recurrent ovarian cancer (ROC) with multidisci-
plinary approach has been developed during the last decade.
The collaboration of highly qualified specialists (chemothera-
peutists, radiologists, oncogynecologists, oncourologists, vas-
cular surgeons, etc.) allows to extend indications for sec-
ondary cytoreductive surgery (SCRS) and to increase the rate
of optimal cytoreduction which are the principal factors for
improved long-term outcomes.
Topographic features of female pelvis contribute to lo-
cal spread of ovarian cancer on the surrounding anatomical
structures including urinary organs that, consequently, should
be operated and restorated during SCRS. The involvement
of urinary organs in ROC is a background of such serious
complications as urinary tract obstruction with further hy-
dronephrosis development, chronic renal failure, infectious
and septic complications, bleeding, urogenital fistula forma-
tion. It significantly impairs the patients’ quality of life and
may limit treatment opportunities as well as worsen long-term
outcomes. Therefore, relevant complex surgical tactics can be
crucial for improving treatment results and social adaptation
of patients with locally advanced ROC.
The objective of the research was to estimate early and
long-term results of SCRS performed for ROC with involve-
ment of urinary organs.
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1. Materials and methods
We retrospectively analyzed the data of 62 patients with ROC
and involvement of urinary organs who underwent SCRS was
performed in the Institute of General and Emergency Surgery
named after V.T. Zaitsev of the Academy of Medical Sciences
of Ukraine during January 2009 – September 2015. The
privacy rights of human subjects were observed.
Selection criteria for SCRS were the following: ROC
with involvement of the bladder and/or the ureter, no urologic
surgery during primary cytoreductive surgery, the ECOG per-
formance status of 0-2. Exclusion criteria for SCRS were the
following: tumor spread beyond the pelvis (carcinomatosis),
distant metastases, ascites, pleural effusion, serious infec-
tious urological complications, septic foci in small pelvis,
decompensated chronic renal insufficiency, severe somatic
pathology.
Preoperative examination was performed in accordance
with clinical standards and protocols [1]. The determination of
serum creatinine level and excretory urography were manda-
tory. Special attention was paid when preoperative creatinine
level had reached more than 150 mg/dL and nephrostomy had
been present.
Urological surgery that had been a subject to the analysis
was the following: cystoscopy with or without intraoperative
urethral stenting, bladder resection, ureterectomy, ureteral
reimplantation, cystectomy with further reconstruction. Eval-
uation criteria included the presence and the level of surgical
and postoperative urological complications within 30 days
after surgery, relaparatomy rates, postoperative mortality, type
of cytoreduction. Postoperative complications were staged
using the Clavien-Dindo classification [2]. Long-term results
were evaluated through recurrence rates after SCRS, median
survival, disease-free survival and overall survival. Survival
data analyses via the Kaplan-Meier method were performed
using SPSS version 17 (SPSS, Chicago, IL, USA).
2. Results
SCRS was performed in 62 patients with ROC. The mean
age was 52±6.2 years (25-76 years). The elevation of crea-
tinine level, hydronephrosis and nephrostomy were found in
2 (3.2%), 9 (14.5%) and 4 (6.4%) cases, respectively. SCRS
was performed through laparotomy. Volumes of performed
surgery (excluding urological one) are listed in Table 1. All
the patients underwent urological surgery during SCRS (Table
2). The Bricker ileal conduit was performed with mucosa-
to-mucosa anastomosis. If total pelvic exenteration was per-
formed, 2 colostomies and ileal conduit were created sepa-
rately.
R0 resections (no visible disease) were performed in all
the cases. Postoperative non-urological complications were
observed in 7 (11.2%) patients. Urological complications
were found in 9 (14.5%) patients, level III-IV urological com-
plications were detected in 3 (4.8%) cases. Postoperative
complications are listed in Table 3.
Table 1. Volume of performed surgery (excluding urological
one)
Surgery n, (%)
Lymphadenectomy 29 (46.7%)
- pelvic + paraaortic 22 (35.5%)
- paraaortic 8 (12.9%)
Bowel resection 17 (27.4%)
- small bowel 5 (8%)
- colorectal 12 (%)
Vascular resections 4 (6.5%)
Other surgeries a 11 (17.7%)
Note.
a - Omentectomy, peritonectomy, appendectomy
Analyzing urological complications, it should be noted
that substantial part was associated with urine leakage through
the anastomosis. It resulted in the formation of vesicovaginal
fistula (n=1) and uretero-abdominal fistula (n=2). Relaparo-
tomy was performed in 3 cases: small bowel obstruction,
bleeding from the external iliac artery, pelvic abscess forma-
tion. 2 patients died within 30 days after surgery; postopera-
tive mortality was 3.2%.
Recurrence was observed in 7 (11.3%) cases (locoregional
recurrence was detected in 5 (8%) patients and systemic re-
currence in 2 (3.2%) patients). Two cases of distant metas-
tases were identified: lung and supraclavicular lymph node
metastases. Median survival was 24 months (2-62 months).
Follow-up mortality was 30% (n=18). In five cases, patient
follow-up was interrupted (median follow-up was 32 months,
range - 11-76 months).
3. Discussion
In past, pelvic exenteration as a palliative procedure for lo-
cally advanced pelvic tumors was proposed by Brunschwig A.
(1948) [3]. Today, combined pelvic surgery is used with cura-
tive intent in order to achieve radical resection and improve
treatment results. According to latest data, a 5-year survival
after pelvic exenteration is more than 50% [4-7]. Goldberg
JM et al. (1998) concluded that the indications for palliative
exenteration should be exceptional and strictly individual, and,
generally, this type of surgery should not be used for palliation
[5]. Nguen DQ et al. (2005) have not shown any survival
improvement after palliative pelvic exenteration [7]. In the
present study, all combined operations were performed as
curative ones with R0.
The complications after pelvic exenteration are often as-
sociated with significant space in the pelvic cavity. It leads
to high rates of intestinal obstruction and fistula formation
in the postoperative period. According to the published data,
locoregional recurrence rate is 24-6% [6, 7, 8-10]. In the
present study, this rate was 11.3% (5 local and 2 systemic).
There was no statistically significant effect of exenteration
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Table 2. Urological surgery during SCRS performed for ROC
Surgery n, (%)
Minimally invasive surgery: 19 (30.6%)
- ureteral stenting 6 (9.7%)
- cystoscopy 13 (20.9%)
Resective surgery:
- bladder resection 26 (41.9%)
- bladder resection without plastic procedures 11 (17.7%)
- bladder and ureter resection with Boari flap reconstruction 5 (8.1%)
- ureter resection with ureterocystoneostomy according to
Politano-Leadbetter
10 (16.1%)
- cystectomy 17 (27.4%)
- anterior pelvic exenteration with the Bricker ileal conduit 7 (11.3%)
- total pelvic exenteration with colostomy and the Bricker
ileal conduit
10 (16.1%)
type and lymph node involvement on survival [6, 7, 9, 10].
4. Conclusions
The results of combined SCRS performed for ROC with in-
volvement of urinary organs indicate the possibility of en bloc
resection of tumor and surrounding organs at acceptable rates
of postoperative complications and mortality. Despite the
localization of ROC involvement of the bladder and/or the
ureter it could be removed. The survival rates of our study
are close to those given in the world literature data. Extended
combined surgery and even pelvic exenteration are effective
in treatment of patients with recurrent ovarian cancer.
5. Prospects for further research
The current study indicates that it is still topically to carry
out research works dedicated not only to surgery for primary
cancer lesions, but also to surgery performed for secondary
cancer lesions. The aggressiveness of local treatment may
be beneficial for patients with ROC; more data are needed to
reject or to adopt this point of view.
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Table 3. Complications after SCRS performed for ROCa
Complication Total, n (%) Grade I-II, n (%) Grade III-IV, n (%)
Early non-urological compli-
cations
13 (21.6%) 10 (16.1%) 3 (4.8%)
Bleeding 1 (1.6%) 1 (1.6%) -
Sepsis 2 (3.2%) 1 (1.6%) 1 (1.6%)
Abdominal abscess 1 (1.6%) 1 (1.6%) -
Wound infection 3 (4.8%) 2 (3.2%) 1 (1.6%)
Heart failure 2 (3.2%) 2 (3.2%) -
Deep vein thrombosis 1 (1.6%) 2 (3.2%) -
Acute renal failure 1 (1.6%) 1 (1.6%) -
Intestinal obstruction 2 (3.2%) - -
Early and late urological
complications
17 (27.4%) 14 (22.5%) 3 (4.8%)
Bladder dysfunction 7 (11.2%) 5 (8%) 2 (3.2%)
Fistulas 3 (4.8%) 3 (4.8%) -
- vesicovaginal 1 (1.6%) 1 (1.6%) -
- uretero-abdominal 2 (3.2%) 1 (1.6%) 1 (1.6%)
Ureteral stenosis 4 (6.5%) 4 (6.5%) -
Note.
a - % of complication was calculated from the total number of patients. Several patients had more than one complication.
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